Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of PBF-680 in moderate to severe COPD
2021-001732-25Phase 2Active
- Sponsor
- Palobiofarma
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing PBF-680 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in plasma eosinophil count at Day 28. Started Jul 2021; status: active.
02
Drugs
PBF-680
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-001732-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001732-25.